Company
Headquarters: Toronto, ON, Canada
C$12.8 Million
CAD as of Jan. 1, 2024
US$9.7 Million
Company | Market Cap (USD) |
---|---|
Thermo Fisher Scientific | $207.62 B |
Danaher | $171.89 B |
Siemens Healthineers AG | $66.05 B |
DexCom, Inc. | $46.50 B |
IDEXX Laboratories, Inc. | $44.72 B |
Company | Market Cap (USD) |
---|---|
Lilly | $586.39 B |
UnitedHealth Group | $504.47 B |
Novo Nordisk | $461.52 B |
Johnson & Johnson | $387.50 B |
Merck | $296.51 B |
Telo Genomics Corp., a biotech company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions. It provides telomere analysis platform with diagnostic and prognostic applications; and solutions with liquid biopsies and related technologies in oncology and neurological diseases. The company's lead application is Telo-MM, a solution that provides actionable information to medical professionals in the treatment of Multiple Myeloma, a form of blood cancer. Its solutions also include TeloView, a proprietary software platform used to quantify specific features of each patient's telomeres. The company serves pathologists, clinicians, academic researchers, and drug developers. Telo Genomics Corp. has a collaboration agreement with the Mayo Clinic to validate its Telo-MM tests for multiple myeloma. The company was formerly known as 3D Signatures Inc. and changed its name to Telo Genomics Corp. in April 2019. Telo Genomics Corp. was incorporated in 2014 and is headquartered in Toronto, Canada.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Telo Genomics Corp has the following listings and related stock indices.
Stock: TSXV: TELO wb_incandescent
Stock: FSX: 3D0A wb_incandescent
Stock: OTC: TDSGF wb_incandescent